Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors or lymphoma. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This ...
See CONTRIBUTING.md for a list of requirements to contribute to this track. It also has a list of tools you can use, of which the test tool is one of them.
The PAYNTR X 002 LE impressed with a runner up finish in the Most Wanted Spikeless Shoe of 2024 test. Comfort and traction are its two strong suits.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results